Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8305409 | 1.00 | ACACB (0.41) | ACACBNPY5RCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL23612991 | 1.00 | ACACB (0.41) | ACACBNPY5RCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL16621807 | 0.83 | ACACB (0.41) | ACACBCHRNB2CHRNB4CHRNA4ALDH1A1 | |
| SCHEMBL18611266 | 0.83 | ACACB (0.41) | ACACBCHRNB2CHRNB4CHRNA4ALDH1A1 | |
| SCHEMBL26343524 | 0.81 | NPY5R (0.35) | ACACBNPY5RCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL5204440 | 0.81 | NPY5R (0.35) | ACACBNPY5RCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL740201 | 0.79 | — | — | |
| SCHEMBL1835719 | 0.78 | ACACB (0.38) | ACACBCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL24654932 | 0.78 | CHRNB2 (0.34) | NPY5RCHRNB2CHRNB4CHRNA4ALDH1A1 | |
| SCHEMBL5205889 | 0.78 | CHRNB2 (0.34) | NPY5RCHRNB2CHRNB4CHRNA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053253-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053253-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | ACACB 3025/4885NPY5R 1510/4885CHRNB2 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.